CLINICAL TRIALS PROFILE FOR VYVGART
✉ Email this page to a colleague
All Clinical Trials for VYVGART
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT05701189 ↗ | Evaluating Efgartigimod in Patients With Guillain-Barré Syndrome | Not yet recruiting | argenx | Phase 2 | 2023-05-01 | The goal of this clinical trial is to evaluate the safety and effectiveness of Efgartigimod in patients with Guillain-Barre syndrome (GBS). The main questions it aims to answer are: - Is Efgartigimod a safe treatment option for GBS patients? - Does treatment with Efgartigimod improve patient outcomes? In addition to standard-of-care procedures and assessments, participants will: - Undergo seven blood draws during hospitalization and in four follow-up study visits to evaluate the concentration of neurofilament light chain, a protein that is elevated in patients with Guillain-Barré syndrome. The presence of neurofilament light chain is believed to be indicative of damage to the nervous system, with higher levels resulting from greater damage. - Complete the Columbia Suicide Severity Rating Scale (C-SSRS) to monitor any suicidal ideation or behaviors during the course of the study. |
| NCT05701189 ↗ | Evaluating Efgartigimod in Patients With Guillain-Barré Syndrome | Not yet recruiting | Chafic Karam | Phase 2 | 2023-05-01 | The goal of this clinical trial is to evaluate the safety and effectiveness of Efgartigimod in patients with Guillain-Barre syndrome (GBS). The main questions it aims to answer are: - Is Efgartigimod a safe treatment option for GBS patients? - Does treatment with Efgartigimod improve patient outcomes? In addition to standard-of-care procedures and assessments, participants will: - Undergo seven blood draws during hospitalization and in four follow-up study visits to evaluate the concentration of neurofilament light chain, a protein that is elevated in patients with Guillain-Barré syndrome. The presence of neurofilament light chain is believed to be indicative of damage to the nervous system, with higher levels resulting from greater damage. - Complete the Columbia Suicide Severity Rating Scale (C-SSRS) to monitor any suicidal ideation or behaviors during the course of the study. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for VYVGART
Condition Name
Clinical Trial Progress for VYVGART
Clinical Trial Phase
Clinical Trial Sponsors for VYVGART
Sponsor Name
